LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...

The FluMist vaccine, manufactured by AstraZeneca, had previously been approved back in 2003 to be given by health care ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

AstraZeneca’s new U.S. spending also leaves in doubt the pharmaceutical company’s plans to invest in a vaccine site in ...

The overall effectiveness of 70% is better than most flu vaccines ... While the Pfizer vaccine is already being rolled out, the Oxford-AstraZeneca one has a crucial advantage - its vials can ...

The FDA has started a review of an extension to the labelling for AstraZeneca’s influenza ... FluMist could become the first self-administered flu vaccine in the US, opening up a new avenue ...

(Reuters) -The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for self-administration, making it the first of its kind. FluMist is the first ...

More than one in two Irish parents say their child missed schools days in the past year due to flu or flu-like symptoms with ...

Eric Le Berrigaud, an analyst from Stifel Nicolaus, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price target remains the same with p14,100.00. Eric Le Berrigaud ...

In a first, the US Food and Drug Administration on Friday approved a nasal spray flu vaccine for self-administration. Starting next fall, AstraZeneca's FluMist, which was authorized in 2003 to be ...

The vaccine FluMist, manufactured by MedImmune, which was acquired by AstraZeneca in 2007 ... FluMist is officially the first ...